Cyanopyridine derivatives as liver X receptor beta agonists, compositions, and their use

A compound having the structural Formula (I):

• or a pharmaceutically acceptable salt thereof, wherein:
• the moiety
• is a divalent moiety selected from the group consisting of
• Y is selected from the group consisting of C(H), C(F), C(Cl), and N,
• R1 is selected from the group consisting of halogen, CN, OH, —(C3-C6)cycloalkyl, —(C1-C4)alkyl, —(C1-C4)haloalkyl, and —(C1-C4)alkoxy;
• R2 is selected from the group consisting of H and halogen;
• R3 is a moiety selected from the group consisting of:
• —C(O)N(RN1)(RN2),
• wherein RN1 and RN2 are each independently selected from the group consisting of H, —NH2, —NH(C1-C4alkyl), —N(C1-C4alkyl)2, —(C1-C4alkyl), —(C2-C6)alkenyl, —(C1-C4)alkoxy, —(C3-C6)cycloalkyl, —CH2(C3-C6)cycloalkyl, phenyl, —(C1-C4)alkylphenyl, heterocycloalkyl, —(C1-C4)alkylheterocycloalkyl, heteroaryl, and —(C1-C4)alkylheteroaryl,
• wherein said —(C1-C4)alkyl, —(C1-C4)alkoxy, phenyl, —(C3-C6)cycloalkyl, heterocycloalkyl, and heteroaryl portions of said RN1 and RN2 are unsubstituted or substituted with one, two, or three groups independently selected from the group consisting of OH, CN, halogen, —NH2, —N(C1-C4alkyl)2, —NH(C1-C4alkyl), —(C1-C4)alkoxy, optionally substituted phenyl, and optionally substituted heteroaryl, wherein said optional substituents on said phenyl are 1 to 3 groups independently selected from OH, CN, —(C1-C4)alkyl, —(C1-C4)alkoxy, and wherein said optional substituents on said heteroaryl are 1 to 3 groups independently selected from —(C1-C4)alkyl, and —(C1-C4)alkoxyl, or, alternatively, RN1 and RN2, together with the nitrogen atom to which they are shown attached, form a 4-, 5-, or 6-membered heteroaryl or partially unsaturated or fully saturated heterocyclic ring comprising (including said nitrogen atom) 1, 2, or 3 ring heteroatoms independently selected from the group consisting of N, O, and S, wherein said heterocyclic ring is unsubstituted or substituted with one, two, or three substitutents independently selected from the group consisting of halo, OH, CN, —(C1-C4)alkyl, amino-substituted —(C1-C4)alkyl, wherein said amino is one, two, or three groups independently selected from the group consisting of —NH2, —N(C1-C4alkyl)2, and —NH(C1-C4alkyl), —(C1-C4)haloalkyl, —(C1-C4)alkyl-OH, phenyl, benzyl, heteroaryl, and —(C1-C4)alkylheteroaryl;
• R4 is selected from the group consisting of H, —CN, halogen, —(C1-C4)alkyl, —(C2-C4)alkenyl, and —(C2-C4)alkynyl, wherein said —(C1-C4)alkyl is optionally substituted with hydroxyl;
• Q is selected from the group consisting of —S(O)2—, —C(O)—, —C(O)O—, and —C(O)C(O)—;
• and
• R5 is selected from the group consisting of
• —(C1-C8)alkyl, —(C1-C8)haloalkyl, —C(OH)(R5A)2, —C(OCH3)(R5A)2, phenyl, —(C1-C4)alkyl-phenyl, cycloalkyl, —(C1-C4)alkyl-cycloalkyl, heterocycloalkyl, —(C1-C4)alkylheterocycloalkyl, heteroaryl, and —(C1-C4)alkyl-heteroaryl,
• wherein each said phenyl, cycloalkyl, and heteroaryl portion of R5 is unsubstituted or substituted with one, two, or three groups independently selected from the group consisting of halogen, CN, —(C1-C6)alkyl, —(C1-C4)haloalkyl, —O(C1-C6)alkyl, —O(C1-C4)haloalkyl, phenyl, and
• wherein each R5A is independently selected from the group consisting of —(C1-C8)alkyl, —(C1-C8)haloalkyl, phenyl, —(C1-C4)alkyl-phenyl, and cycloalkyl, wherein said phenyl and said cycloalkyl portion of R5A is unsubstituted or substituted with one, two, or three groups independently selected from the group consisting of halogen, CN, —(C1-C6)alkyl, —(C1-C4)haloalkyl, —O(C1-C6)alkyl, and —O(C1-C4)haloalkyl.